Antiretroviral Treatment Changes among HIV, Hepatitis B Virus and Hepatitis C Virus Coinfected Australian Patients

The objectives of the current study were to assess the impact of HAART on rates of change of antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in the Australian HIV Observational Database (AHOD).

The analysis was based on 805 of the 2218 patients recruited to the AHOD by March 2003, who had commenced HAART after 1 January 1997, who had recorded test results for HBV surface antigen (HBsAg) and anti-HCV antibody, and who had follow-up of more than 3 months.

The effect of hepatitis coinfection on the rate of antiretroviral treatment change after commencing HAART was assessed using a random-effect Poisson regression model.

Results

· Among those included in the analyses, the prevalences of HBV and HCV were 4.8% and 12.8%, respectively.

· The overall rate of combination antiretroviral treatment change was 0.74 combinations per year.

· Factors independently associated with an increased rate of change of combination antiretroviral treatment were: prior AIDS-defining illness; prior exposure to double combination antiretroviral therapy; and antiretroviral treatment class.

· Coinfection with HBV and/or HCV was not found to be significantly associated with the rate of combination antiretroviral treatment change.

The authors conclude, “While both HBV and HCV coinfections are relatively common in the AHOD, they do not appear to be serious impediments to the treatment of HIV-infected patients.”

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia.

05/11/05

Reference
K Petoumenos and C Ringland (on behalf of the Australian HIV Observational Database).  Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Medicine 6(3):155-63. May 2005.